I appreciate the comment, these are important points that I did not include in the post and I didn’t mean to imply otherwise when posting this.

I thought this article was worth sharing because some people promoting these products still say/imply that they can be used temporarily. Some people may start treatment without fully understanding the details:

Some studies have found that about half of people who start taking a GLP-1 drug for weight loss stop taking it within a year—for various reasons—and many people think they can stop taking anti-obesity drugs once they’ve reached a desired weight, Oczypok and Anderson write. But that’s not in line with the data.

This part was also interesting. If there IS a way to stop taking the drugs after a while, or safer ways to wean patients off the drugs if they can no longer continue, then that is worth investigating:

Data gaps and potential off-ramps

On the other hand, there were 54 participants of the 308 (17.5 percent) who didn’t regain a significant amount of weight (less than 25 percent.) This group saw some of their health metrics worsen on withdrawal of the drug, but not all—blood pressure increased a bit, but cholesterol didn’t go up significantly overall. About a dozen participants (4 percent of the 308) continued to lose weight after stopping the drug.

The researchers couldn’t figure out why these 54 participants fared so well; there were “no apparent differences” in demographic or clinical characteristics, they reported. It’s clear the topic requires further study.

Oczypok and Anderson highlight that the study involved an abrupt withdrawal from the drug. In contrast, many patients may be interested in slowly weaning off the drugs, stepping down dosage levels over time. So far, data on this strategy and the protocols to pull it off have little data behind them. It also might not be an option for patients who abruptly lose access to or insurance coverage for the drugs. Other strategies for weaning off the drugs could involve ramping up physical activity or calorie restriction in anticipation of dropping the drugs, the experts note.

In addition to more data on potential GLP-1 off-ramps, the pair calls for more data on the effects of weight fluctuations from people going on and off the treatment. At least one study has found that the regained weight after intentional weight loss may end up being proportionally higher in fat mass, which could be harmful.

For now, Oczypok and Anderson say doctors should be cautious about talking with patients about these drugs and what the future could hold. “These results add to the body of evidence that clinicians and patients should approach starting [anti-obesity medications] as long-term therapies, just as they would medications for other chronic diseases.”